Oberholzer-Gee, Felix. "Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)." Harvard Business School Teaching Note 707-542, March 2007.
It is the active component in Amgen's blockbuster drug Epogen, US sales of which rose 21% to $1.8 billion in 1999. Amgen accused TKT of infringing five US patents, which claim EPO and its ...
For the best part of a decade, Amgen's Epogen has been the best-selling biotech drug. This situation has now changed with the appearance of two arthritis drugs—Centocor's Remicade and Immunex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results